We are the future of gene therapy
At Affinia Therapeutics, we’re singularly focused on using innovations in gene therapy to lead the fight against devastating rare and prevalent diseases. We're working to find solutions to the limitations of conventional AAV capsids, promoters, and manufacturing approaches to improve tissue targeting, cell expression, packaging efficiency, and manufacturing quality, yields, and scalability. We stand determined to expand what gene therapy can and will do.
It all started with breakthrough science led by our scientific founder, Luk Vandenberghe, Ph.D., a pioneer in the field and inventor of AAV9, his student, Eric Zinn, Ph.D., and team, who brought their passion to the field of AAV gene therapy to advance it toward its full potential. Using computational design and high-throughput screening methods, a deep understanding of the underlying structure of the AAV was achieved and a new class of AAV capsids was enabled - one with novel properties and therapeutic possibilities vs. traditional capsids. Together with fellow pioneers Botond Roska, M.D., Ph.D., an expert in the design of next-generation promoters, and Aaron Tward, M.D., Ph.D., renowned for his expertise in high-throughput sequencing technologies, they founded Affinia Therapeutics. We’ve assembled a team of experienced industry leaders who want to see gene therapy's full potential realized. Together, we’re pioneering a new class of gene therapies.
At Affinia Therapeutics, we call it ART: Affinia Rationally-designed Therapies. Our platform for rational design of capsids, promoters, and manufacturing approaches is designed to benefit any genetic modality employed, such as gene replacement, vectorized antibody, gene editing, or RNA knockdown. Similarly, our ART platform is designed to be applicable to any tissue of interest including the CNS, muscle, lung, heart, kidney, liver, or eye.
Propelling the promise of gene therapy, with purpose
Whether through small steps or giant leaps, we strive each day to advance the gene therapy field with our expertise, experience, and collaborative thinking. Using our proprietary platform, we design and develop capsids and promoters to methodically alter how gene therapies work in the body, and novel manufacturing approaches to improve quality, yields, and scalability. We’re expanding the utility of gene therapies as a transformative delivery mechanism for therapeutics to reach new tissues and address new diseases. We’re purposeful in what we do, driven to bring the hope of gene therapy to people living with a wider range of devastating diseases.
What we’re working on
Affinia Therapeutics is committed to transforming gene therapy with our platform and pipeline — to push science forward, to impact human medicine, and to give patients the options they deserve.Our pipeline